

Name: Bröckelmann, Paul Jan; Priv.-Doz. Dr. med.  
\*03.08.1987 in Cologne, Germany

Positions: Attending Physician, University Hospital Cologne  
Physician Scientist, MPI for Biology of Ageing  
PhD Candidate (IPMM), University of Cologne

Contact: University Hospital of Cologne  
Department I of Internal Medicine  
Kerpener Str. 62, D-50935 Cologne, Germany  
Mobile: +49-(0)177-7446555  
Paul.Broeckelmann@uk-koeln.de

Family: Married, 3 children (\*2016, \*2019, \*2021)



## Education and Academic Training

---

2022 *Venia legendi* (Priv.-Doz.) for Internal Medicine, University of Cologne

2013 – 2016 MD thesis Department I of Internal Medicine, University of Cologne  
Title: "Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma". Supervisor: Prof. A. Engert

2007 – 2013 Medical school, University of Cologne  
2013 Brighton Sussex Medical School (Internship Medicine), UK  
2012 Universidad Buenos Aires (Internship Surgery), Argentina  
2012 Kilimanjaro Christian Medical Center (Internship Medicine), Tanzania  
2010 Istanbul Cerrahpasa University (EU Erasmus Program), Turkey  
2009 - 2013 Scholarship for outstanding students (Cusanuswerk)

2006 – 2007 Federal Civil Service at St. Marien Hospital Cologne, Germany

## Professional Appointments & Qualifications

---

since 05/2024 Attending Physician Hematology and Medical Oncology, Department I of Internal Medicine, University Hospital of Cologne, Germany

02/2023 Board exam "Specialist Medical Oncology and Hematology, North-Rhine Westphalia Medical Chamber (Ärztekammer Nordrhein), Germany

since 01/2021 Postdoctoral Physician Scientist, Research Group Jachimowicz, Max-Planck Institute for the Biology of Ageing, Cologne

2019 – 2020 Freelancing Emergency Care Physician, Fire Department Cologne

11/2019 Board exam "Specialist Internal Medicine", North-Rhine Westphalia Medical Chamber (Ärztekammer Nordrhein), Germany

03/2019 Board exam "Specialist Emergency Care", North-Rhine Westphalia Medical Chamber (Ärztekammer Nordrhein), Germany

03 – 05/2015 Memorial Sloan Kettering Cancer Center; Lymphoma Unit, Bone Marrow Transplantation & Laboratory; New York City, USA (Prof. A. Younes)

2014 – 2024 Physician Department I of Internal Medicine for Hematology & Oncology, University Hospital of Cologne, Germany (Prof. M. Hallek)

since 01/2014 Trial Physician German Hodgkin Study Group (GHSG, Prof. A. Engert)

## Administrative Duties & Activities

since 04/2024	Co-Speaker of “Immune-Oncology Working Group” of the German National Cancer Centers (NCT)
2022 – 2024	Member “Immune-Oncology Task Force” of the German National Cancer Centers (NCT)
since 2022	Coordinating author of S3 guideline “Immune-related adverse events” within the framework of the Leitlinienprogramm Onkologie (DKH/DKG)
since 08/2020	Founder Interdisciplinary Board for Immune-Mediated Toxicities (iTTox) Center for Integrated Oncology (CIO) Aachen Bonn Cologne Düsseldorf
2019 – 2021	Representative of the Resident Physicians Department I of Internal Medicine, University Hospital of Cologne, Germany
since 2018	Grant review for funding bodies (e.g. German Cancer Aid (DKH), European Hematology Association (EHA), Jose-Carreras Leukemia Foundation (DJCLS), ZonMw (The Netherlands))
since 10/2017	Symposium Co-Chair and Organizing Committee “International Symposium on Hodgkin Lymphoma” (ISHL, Cologne, Germany)
since 2016	Peer review for scientific journals (e.g. JCO, Blood, JITC, JNCI, Blood Cancer Journal, Haematologica, Blood Advances, Scientific Reports, BJH, EJC, JCO CCI, Annals of Hematology and others)

## Selected Third-Party Funding, Honors & Awards

since 02/2024	Excellence Stipend of Else-Kröner-Fresenius Foundation (EKFS)
07/2023 – 07/2024	Clinician Scientist Research Position of SFB1530, German Research Foundation (DFG)
05/2023	Abstract Award and Travel Grant ICML 2023 (Lugano, Switzerland)
01/2021 – 06/2023	Mildred Scheel School of Oncology (MSSO) Clinician Scientist Fellowship, German Cancer Aid (DKH)
2019 – 2022	3x Abstract Achievement Award American Society of Hematology (ASH) Annual Meeting (2019, 2020, 2022; USA)
2017 – 2018	EHA Clinical Research Training in Hematology (CRTH)
07/2017 – 07/2020	Translational Research Consortium “Immune Checkpoint Inhibition in Early-Stage Hodgkin Lymphoma”, German Cancer Aid (DKH)
2016 – 2017	2x Abstract Awards and Travel Grant EHA Annual Meetings 2016, 2017
2015 – 2016	EHA Master Class Hematology

## Memberships

AACR, DGHO, EHA, ESMO, GLA and SITC

Cologne, 30-NOV-2024



Priv.-Doz. Dr. med. Paul J. Bröckelmann

Heger JM, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, Kirst E, Reinke S, Klapper W, **Bröckelmann PJ**, Ferdinandus J, Kaul H, Schneider G, Schneider J, Schleifenbaum JK, Ullrich RT, Freihammer M, Awerkiew S, Lohmann M, Klein F, Nürnberg P, Hallek M, Rossi D, Mauz-Körholz C, Gattenlöhner S, Bräuninger A, Borchmann P, von Tresckow B, Borchmann S. *J Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma*. **J Clin Oncol**. 2024 Sep 30;JCO2301867. doi: 10.1200/JCO.23.01867. Online ahead of print. PMID: 39348625 . **IF 50.8**

**Bröckelmann PJ**<sup>#</sup>, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. *Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial*. **J Clin Oncol**. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. **IF 50.8** <sup>#corresponding author</sup>

Garcia-Marquez MA, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, Veldman J, Borchmann S, Rosenwald A, Sasse S, Diepstra A, Borchmann P, Engert A, Klapper W, von Bergwelt-Baildon M, **Bröckelmann PJ**<sup>#</sup>, Schlößer HA\*. *Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma*. **Leukemia** 2021 Sep 28. doi: 10.1038/s41375-021-01421-z. **IF 12.9** <sup>\*equal contribution, #corresponding author</sup>

Voltin CA, Mettler J, van Heek L, Goergen H, Müller H, Baues C, Keller U, Meissner J, Trautmann-Grill K, Kerkhoff A, Fuchs M, Sasse S, von Tresckow B, Dietlein M, Borchmann P, Engert A, Kobe C\*, **Bröckelmann PJ**<sup>#</sup>. *Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial*. **Clin Cancer Res** 2021 Jan 15;27(2):402-407. doi: 10.1158/1078-0432.CCR-20-3303. **IF 13.8** <sup>\*equal contribution, #corresponding author</sup>

**Bröckelmann PJ**<sup>#</sup>, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A. *Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy*. **J Clin Oncol** 2021 Jan 10;39(2):107-115. doi: 10.1200/JCO.20.00947. **IF 50.8** <sup>#corresponding author</sup>

Reinke S\*, **Bröckelmann PJ**<sup>\*</sup>, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F, Kotrova M, Pal K, Brüggemann M, Hartmann E, Sasse S, Kobe C, Mathas S, Soekler M, Keller U, Bormann M, Zimmermann A, Richter J, Fuchs M, von Tresckow B, Borchmann P, Schlößer H, von Bergwelt-Baildon M, Rosenwald A, Engert A, Klapper W. *Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1*. **Blood** 2020 Dec 17;136(25):2851-2863. doi: 10.1182/blood.2020008553. <sup>\*equal contribution</sup> **IF 25.5**

**Bröckelmann PJ**, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A. *Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial*. **JAMA Oncol** 2020 Jun 1;6(6):872-880. **IF 33.0**

**Bröckelmann PJ**, Müller H, Kücüksarioglan E, Kaskel P, Metterlein V, Giezek H, Balakumaran A, Raut MK, Engert A, von Tresckow B. *Outcomes of Patients with 3rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group*. **Ann Oncol** 2019 Mar 1;30(3):490-491 **IF 51.8**

**Bröckelmann PJ**, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall S, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A. *Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma*. **Ann Oncol** 2017 Jun 1;28(6):1352-1358. **IF 51.8**

**Bröckelmann PJ**, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, Meissner J, Kerkhoff A, Ludwig WD, Fuchs M, Borchmann P, Engert A. *Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials* **J Clin Oncol** 2017 May 1;35(13):1444-1450. **IF 50.8**